{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:24:18Z","timestamp":1790666658210,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.autrev.2007.03.009","type":"journal-article","created":{"date-parts":[[2007,4,17]],"date-time":"2007-04-17T11:17:27Z","timestamp":1176808647000},"page":"529-536","source":"Crossref","is-referenced-by-count":44,"title":["Potential target of infliximab in autoimmune and inflammatory diseases"],"prefix":"10.1016","volume":"6","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Turiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2007.03.009_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.copbio.2004.09.005","article-title":"Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases","author":"Taylor","year":"2004","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.autrev.2007.03.009_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.gtc.2004.02.014","article-title":"Treatment of luminal and fistulizing Crohn's disease with infliximab","volume":"33","author":"Comerford","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.autrev.2007.03.009_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2007.03.009_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2007.03.009_bib5","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1126\/science.279.5353.1052","article-title":"Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis","volume":"279","author":"Clynes","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.autrev.2007.03.009_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","article-title":"Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus","volume":"35","author":"Studnicka-Benke","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib9","first-page":"S378","article-title":"Anti TNF therapy of SLE is feasible and apparently effective","volume":"48","author":"Aringer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib10","first-page":"S379","article-title":"Frequent infusion reaction associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus","volume":"48","author":"Katz","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extensive follow up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2007.03.009_bib12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for TNF-inhibitors in the treatment of resistant dermatomyositis and polymyositis","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.009_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Club Rhumatismes et Inflammation","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.009_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/ard.2005.042416","article-title":"Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis","volume":"64","author":"Mukhtyar","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.009_bib15","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib16","article-title":"The role of infliximab in a pedriatic patient with polyarteritis nodosa","volume":"48","author":"Whitney-Mahoney","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14656566.5.1.25","article-title":"Recent progress in the pharmacotherapy of Churg\u2013Strauss syndrome","volume":"5","author":"Hellmich","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2007.03.009_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","article-title":"Infliximab treatment for refractory Kawasaki syndrome","volume":"146","author":"Burns","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2007.03.009_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11936-005-0015-1","article-title":"Behcet's disease: current therapeutic perspectives","volume":"7","author":"Leiba","year":"2005","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.autrev.2007.03.009_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2007.03.009_bib21","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of longstanding active giant cell arteritis with infliximab: report of four cases","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","article-title":"Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis","volume":"62","author":"Andonopoulos","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.03.009_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.berh.2004.06.003","article-title":"Polymyalgia rheumatica","volume":"18","author":"Salvarani","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib24","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","article-title":"Sarcoidosis TNF-alpha release from alveolar macrophages and serum level of IL-2R are prognostic markers","volume":"156","author":"Ziegenhagen","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2007.03.009_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","article-title":"Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis","volume":"53","author":"Sweiss","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib27","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","article-title":"Effectiveness of infliximab in treating selected patients with sarcoidosis","volume":"100","author":"Saleh","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2007.03.009_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2007.03.009_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.03.009_bib30","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B and C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib31","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2007.03.009_bib33","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/01.brs.0000141179.58778.6c","article-title":"Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up","volume":"29","author":"Korhonen","year":"2004","journal-title":"Spine"},{"key":"10.1016\/j.autrev.2007.03.009_bib34","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1097\/01.brs.0000190815.13764.64","article-title":"The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study","volume":"30","author":"Korhonen","year":"2005","journal-title":"Spine"},{"key":"10.1016\/j.autrev.2007.03.009_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kei221","article-title":"In SAPHO syndrome anti-TNF-{alpha} therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations","volume":"45","author":"Massara","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2007.03.009_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2007.03.009_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-005-1122-9","article-title":"Familial Mediterranean fever responds well to infliximab: single case experience","volume":"25","author":"Ozgocmen","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2007.03.009_bib39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10227-005-0110-7","article-title":"Off-label dermatologic uses of anti-TNF-\u03b1 therapies","volume":"9","author":"Alexis","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.autrev.2007.03.009_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17402520500134254","article-title":"Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab","volume":"12","author":"Foster","year":"2005","journal-title":"Clin Dev Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T06:51:28Z","timestamp":1546930288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997207000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1568997207000808"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2007.03.009","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}